{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:20:01Z","timestamp":1790403601012,"version":"4.1.0"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Despite a prevailing view that advances in cancer therapy will come through selective targeting of enzymes encoded by mutated oncogenes responsible for the neoplastic phenotype, recent advances in the treatment of patients with chronic lymphocytic leukemia (CLL) have instead exploited knowledge of its biology. Indeed, CLL cells depend on interactions with cells and soluble factors present in the tumor microenvironment for proliferation and survival. B-cell receptor signaling and chemokine-receptor signaling play prominent roles. Elucidation of these signaling pathways has defined physiologic targets for drugs, such as ibrutinib, which inhibit Bruton tyrosine kinase and are therapeutically effective. The characteristic high-level expression of BCL2 in CLL that can enhance leukemia-cell survival has now become an Achilles heel targeted by clinically effective drugs such as venetoclax. Here we discuss advances in such targeted therapy and highlight other disease attributes, such as the distinctive expression of ROR1, which may be targeted for clinical benefit, alone or in combination with other targeted therapies.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000416","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T06:32:50Z","timestamp":1574663570000},"page":"378-385","source":"Crossref","is-referenced-by-count":40,"title":["Targeted Therapy in Chronic Lymphocytic Leukemia"],"prefix":"10.1097","volume":"25","author":[{"given":"Thomas J.","family":"Kipps","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Y.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00002512-200522120-00002","article-title":"Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies","volume":"22","year":"2005","journal-title":"Drugs Aging"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1517\/14656566.2012.693163","article-title":"Bendamustine for treatment of chronic lymphocytic leukemia","volume":"13","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.leukres.2013.05.004","article-title":"Fludarabine: a review of the clear benefits and potential harms","volume":"37","year":"2013","journal-title":"Leuk Res"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"bib5-20230924","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"bib8-20230924","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10428190290011921","article-title":"Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells","volume":"43","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1182\/blood.V96.8.2655","article-title":"Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell\u2013derived factor-1","volume":"96","year":"2000","journal-title":"Blood"},{"key":"bib10-20230924","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V99.3.1030","article-title":"Distinctive features of \u201cnurselike\u201d cells that differentiate in the context of chronic lymphocytic leukemia","volume":"99","year":"2002","journal-title":"Blood"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2002-03-0841","article-title":"CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway","volume":"101","year":"2003","journal-title":"Blood"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2011-01-333682","article-title":"ZAP-70 enhances migration of malignant B lymphocytes toward CCL21 by inducing CCR7 expression via IgM-ERK1\/2 activation","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib13-20230924","first-page":"4419","article-title":"The role of hyaluronan and interleukin 8 in the migration of chronic lymphocytic leukemia cells within lymphoreticular tissues","volume":"59","year":"1999","journal-title":"Cancer Res"},{"key":"bib14-20230924","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1073\/pnas.1221841110","article-title":"Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44","volume":"110","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1182\/blood-2007-08-109249","article-title":"Alpha4beta1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B\/MMP-9 in chronic leukemic but not in normal B cells","volume":"112","year":"2008","journal-title":"Blood"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-15-2095","article-title":"The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2004-03-0889","article-title":"Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha","volume":"106","year":"2005","journal-title":"Blood"},{"key":"bib18-20230924","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1158\/0008-5472.CAN-08-4173","article-title":"CD38\/CD31, the CCL3 and CCL4 chemokines, and CD49d\/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival","volume":"69","year":"2009","journal-title":"Cancer Res"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2119\/molmed.2009.00146","article-title":"CD38\/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells","volume":"16","year":"2010","journal-title":"Mol Med"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","year":"2009","journal-title":"Blood"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/bjh.12401","article-title":"Enhancement of CD154\/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia","volume":"162","year":"2013","journal-title":"Br J Haematol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1182\/blood.2019001366","article-title":"Cirmtuzumab blocks Wnt5a\/ROR1 stimulation of NF-\u03baB to repress autocrine STAT3 activation in chronic lymphocytic leukemia","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib23-20230924","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s00277-011-1218-z","article-title":"Chronic lymphocytic leukemia cells induce anti-apoptotic effects of bone marrow stroma","volume":"90","year":"2011","journal-title":"Ann Hematol"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2796.2008.02030.x","article-title":"Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation","volume":"264","year":"2008","journal-title":"J Intern Med"},{"key":"bib26-20230924","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","year":"2011","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","year":"2012","journal-title":"Blood"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","year":"2018","journal-title":"Leukemia"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","year":"2015","journal-title":"N Engl J Med"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/ajh.25259","article-title":"Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-na\u00efve patients with chronic lymphocytic leukemia: a cross-trial comparison of phase 3 studies","volume":"93","year":"2018","journal-title":"Am J Hematol"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.15421","article-title":"Evaluation of 230 patients with relapsed\/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials","volume":"182","year":"2018","journal-title":"Br J Haematol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib36-20230924","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","year":"2008","journal-title":"Blood"},{"key":"bib37-20230924","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib38-20230924","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2019.0002","article-title":"NCCN guidelines insights: chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 2.2019","volume":"17","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"bib39-20230924","first-page":"1278","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib40-20230924","doi-asserted-by":"crossref","first-page":"13906","DOI":"10.1073\/pnas.1409362111","article-title":"Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL)","volume":"111","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib41-20230924","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"bib42-20230924","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(14)71182-9","article-title":"Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial","volume":"16","year":"2015","journal-title":"Lancet Oncol"},{"key":"bib43-20230924","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S1470-2045(16)30212-1","article-title":"Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib44-20230924","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-na\u00efve and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib45-20230924","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.14660","article-title":"Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib","volume":"178","year":"2017","journal-title":"Br J Haematol"},{"key":"bib46-20230924","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1200\/JOP.2014.002469","article-title":"Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels","volume":"11","year":"2015","journal-title":"J Oncol Pract"},{"key":"bib47-20230924","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.clml.2018.08.007","article-title":"Improvement in parameters of hematologic and immunologic function and patient well-being in the phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"18","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib48-20230924","first-page":"4642831","article-title":"Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib","volume":"2016","year":"2016","journal-title":"Case Rep Infect Dis"},{"key":"bib49-20230924","first-page":"27","article-title":"Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia","volume":"21","year":"2017","journal-title":"Respir Med Case Rep"},{"key":"bib50-20230924","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hon.2387","article-title":"Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma","volume":"36","year":"2018","journal-title":"Hematol Oncol"},{"key":"bib51-20230924","first-page":"6514604","article-title":"Amebic encephalitis in a patient with chronic lymphocytic leukemia on ibrutinib therapy","volume":"2018","year":"2018","journal-title":"Case Rep Hematol"},{"key":"bib52-20230924","doi-asserted-by":"crossref","first-page":"62","DOI":"10.14740\/wjon1099w","article-title":"Cutaneous mucormycosis following a bullous pemphigoid flare in a chronic lymphocytic leukemia patient on ibrutinib","volume":"9","year":"2018","journal-title":"World J Oncol"},{"key":"bib53-20230924","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.blre.2018.04.007","article-title":"Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies","volume":"32","year":"2018","journal-title":"Blood Rev"},{"key":"bib54-20230924","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/10428194.2017.1347931","article-title":"Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies","volume":"59","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"bib55-20230924","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/1078-0432.CCR-16-1431","article-title":"Extended treatment with single-agent ibrutinib at the 420 mg dose leads to durable responses in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"23","year":"2017","journal-title":"Clin Cancer Res"},{"key":"bib56-20230924","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib57-20230924","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","year":"2017","journal-title":"Cancer"},{"key":"bib58-20230924","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib59-20230924","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","year":"2015","journal-title":"Blood"},{"key":"bib60-20230924","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjh.14062","article-title":"Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors","volume":"177","year":"2017","journal-title":"Br J Haematol"},{"key":"bib61-20230924","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib62-20230924","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood-2015-08-664086","article-title":"A phase 1 clinical trial of the selective BTK inhibitor ONO\/GS-4059 in relapsed and refractory mature B-cell malignancies","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib63-20230924","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","year":"2019","journal-title":"Blood"},{"key":"bib64-20230924","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/13543784.2018.1404027","article-title":"Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with chronic lymphocytic leukemia (CLL)","volume":"27","year":"2018","journal-title":"Expert Opin Investig Drugs"},{"key":"bib65-20230924","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood-2017-02-765115","article-title":"Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO\/GS-4059","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib66-20230924","doi-asserted-by":"crossref","first-page":"e11716","DOI":"10.1371\/journal.pone.0011716","article-title":"Elucidating the CXCL12\/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis","volume":"5","year":"2010","journal-title":"PLoS One"},{"key":"bib67-20230924","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib68-20230924","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib69-20230924","article-title":"Idelalisib-induced pneumonitis","volume":"2016","year":"2016","journal-title":"BMJ Case Rep"},{"key":"bib70-20230924","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1097\/PAS.0000000000000522","article-title":"Idelalisib-associated colitis: histologic findings in 14 patients","volume":"39","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"bib71-20230924","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib72-20230924","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib73-20230924","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/13543784.2017.1312338","article-title":"Duvelisib: a phosphoinositide-3 kinase \u03b4\/\u03b3 inhibitor for chronic lymphocytic leukemia","volume":"26","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"bib74-20230924","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.2217\/fon-2018-0881","article-title":"Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia","volume":"15","year":"2019","journal-title":"Future Oncol"},{"key":"bib75-20230924","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s40265-018-1013-4","article-title":"Duvelisib: first global approval","volume":"78","year":"2018","journal-title":"Drugs"},{"key":"bib76-20230924","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","year":"2019","journal-title":"Lancet Haematol"},{"key":"bib77-20230924","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib78-20230924","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","year":"2013","journal-title":"Nat Med"},{"key":"bib79-20230924","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/path.1768","article-title":"Expression of the NF-kappaB targets BCL2 and BIRC5\/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively","volume":"206","year":"2005","journal-title":"J Pathol"},{"key":"bib80-20230924","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/sj.leu.2403623","article-title":"Chronic lymphocytic leukemia cells display p53-dependent drug-induced PUMA upregulation","volume":"19","year":"2005","journal-title":"Leukemia"},{"key":"bib81-20230924","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-015-2585-7","article-title":"Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review","volume":"95","year":"2016","journal-title":"Ann Hematol"},{"key":"bib82-20230924","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"bib83-20230924","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"key":"bib84-20230924","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib85-20230924","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed\/refractory chronic lymphocytic leukemia","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib86-20230924","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib87-20230924","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.clml.2019.05.013","article-title":"SOHO state of the art updates and next questions: the conundrum in assessing the therapy response of patients with chronic lymphocytic leukemia","volume":"19","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib88-20230924","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"A fixed duration of venetoclax-rituximab in relapsed\/refractory CLL eradicates minimal residual disease and prolongs survival: long-term outcomes of the MURANO phase III study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib89-20230924","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib90-20230924","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","year":"2017","journal-title":"Blood"},{"key":"bib91-20230924","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","year":"2016","journal-title":"Semin Oncol"},{"key":"bib92-20230924","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib93-20230924","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"key":"bib94-20230924","first-page":"e188","article-title":"Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma","volume":"186","year":"2019","journal-title":"Br J Haematol"},{"key":"bib95-20230924","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","year":"2014","journal-title":"Blood"},{"key":"bib96-20230924","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cdd.2017.188","article-title":"Bcl-2 on the brink of breakthroughs in cancer treatment","volume":"25","year":"2018","journal-title":"Cell Death Differ"},{"key":"bib97-20230924","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-07-1823","article-title":"Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia","volume":"14","year":"2008","journal-title":"Clin Cancer Res"},{"key":"bib98-20230924","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/ijc.23587","article-title":"Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy","volume":"123","year":"2008","journal-title":"Int J Cancer"},{"key":"bib99-20230924","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","year":"2012","journal-title":"Am J Pathol"},{"key":"bib100-20230924","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","article-title":"ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia","volume":"35","year":"2011","journal-title":"Leuk Res"},{"issue":"15 suppl","key":"bib101-20230924","first-page":"S167","article-title":"Pre-clinical specificity and safety of UC-961, a first-in-class monoclonal antibody targeting ROR1","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"bib102-20230924","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ror1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","year":"2018","journal-title":"Cell Stem Cell"},{"key":"bib103-20230924","first-page":"585","article-title":"Wnt5a induces ROR1\/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"bib104-20230924","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.1308374111","article-title":"ROR1 can interact with TCL1 and enhance leukemogenesis in E\u03bc-TCL1 transgenic mice","volume":"111","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib105-20230924","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2016-04-712562","article-title":"High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia","volume":"128","year":"2016","journal-title":"Blood"},{"key":"bib106-20230924","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib107-20230924","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16-1 cluster functions in human leukemia","volume":"105","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib108-20230924","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood-2009-10-249367","article-title":"13q14 Deletions in CLL involve cooperating tumor suppressors","volume":"115","year":"2010","journal-title":"Blood"},{"key":"bib109-20230924","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib110-20230924","doi-asserted-by":"crossref","first-page":"10731","DOI":"10.1073\/pnas.1708264114","article-title":"MicroRNA dysregulation to identify therapeutic target combinations for chronic lymphocytic leukemia","volume":"114","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib111-20230924","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood-2018-99-119447","article-title":"Development of cirmtuzumab antibody-drug conjugates (ADCs) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1)","volume":"132","year":"2018","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:14:14Z","timestamp":1695532454000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":111,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000416","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}